Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Accumulated Expenses data on file, last reported at $43.3 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 16.92% year-over-year to $43.3 million in Q2 2026; TTM through May 2026 was $43.3 million, a 16.92% increase from a year earlier, with the FY2025 full-year figure at $54.9 million, up 44.37% from the prior year.
• Accumulated Expenses for Q2 2026 stood at $43.3 million, down from $60.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for NRIX reached as high as $60.0 million in Q1 2026 and fell as low as $11.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $30.8 million across 5 years, with a median of $26.4 million in 2023.
• Across the five-year window, Accumulated Expenses soared 157.02% in 2022 and slipped 8.33% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $22.4 million in 2022, then rose by 11.33% to $25.0 million in 2023, then surged by 52.16% to $38.0 million in 2024, then soared by 44.37% to $54.9 million in 2025, then decreased by 21.12% to $43.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $43.3 million in Q2 2026, $60.0 million in Q1 2026, and $54.9 million in Q4 2025.